minimal Common Oncology Data Elements (mCODE) Implementation Guide
4.0.0 - STU4 United States of America flag

minimal Common Oncology Data Elements (mCODE) Implementation Guide, published by HL7 International / Clinical Interoperability Council. This guide is not an authorized publication; it is the continuous build for version 4.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-mCODE-ig/ and changes regularly. See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 Home
... 2 Patient Information
... 3 Disease Characterization
... 4 Assessment
... 5 Genomics
... 6 Treatments
... 7 Outcomes
... 8 Conformance Expectations
... 9 Identifying In-Scope Patients
... 10 Profile Conformance
... 11 USCDI+ Cancer Conformance
... 12 Terminology
... 13 Data Dictionary
... 14 Profiles
... 15 Extensions
... 16 Value Sets
... 17 Code Systems
... 18 Capability Statements
... 19 Artifacts Summary
.... 19.1 mCODE Data Receiver CapabilityStatement: Get in-scope patients (and associated Conditions) using _include
.... 19.2 mCODE Data Receiver CapabilityStatement: Get in-scope patients using reverse chaining
.... 19.3 mCODE Data Receiver: Get Bundle for a Patient
.... 19.4 mCODE Data Receiver: Get Conditions then Patients
.... 19.5 mCODE Data Receiver: Get Patients in Group
.... 19.6 mCODE Data Sender CapabilityStatement: Get in-scope patients (and associated Conditions) using _include
.... 19.7 mCODE Data Sender CapabilityStatement: Get in-scope patients using reverse chaining
.... 19.8 mCODE Data Sender: Get Bundle for a Patient
.... 19.9 mCODE Data Sender: Get Conditions then Patients
.... 19.10 mCODE Data Sender: Get Patients in Group
.... 19.11 Fetch mCODE Patient Bundle for a given Patient
.... 19.12 Search by code:in in Conditions
.... 19.13 Cancer Risk Assessment Profile
.... 19.14 Parent for T, N, and M Categories.
.... 19.15 ALL Risk Assessment Profile
.... 19.16 Body Surface Area
.... 19.17 Cancer Disease Status Profile
.... 19.18 Cancer Patient Profile
.... 19.19 Cancer Stage Profile
.... 19.20 Cancer-Related Medication Administration Profile
.... 19.21 Cancer-Related Medication Request Profile
.... 19.22 Cancer-Related Surgical Procedure Profile
.... 19.23 Comorbidities Profile
.... 19.24 Deauville Scale Profile
.... 19.25 ECOG Performance Status Profile
.... 19.26 Genomic Region Studied Profile
.... 19.27 Genomic Variant Profile
.... 19.28 Genomics Report Profile
.... 19.29 Histologic Behavior and Type
.... 19.30 Histologic Grade
.... 19.31 History of Metastatic Cancer
.... 19.32 Human Specimen Profile
.... 19.33 Karnofsky Performance Status Profile
.... 19.34 Lansky Play Performance Status Profile
.... 19.35 Lymphoma Stage Profile
.... 19.36 mCODE Patient Bundle Profile
.... 19.37 mCODE Patient Group Profile
.... 19.38 Primary Cancer Condition Profile
.... 19.39 Radiotherapy Course Summary Profile
.... 19.40 Radiotherapy Volume Profile
.... 19.41 Rhabdomyocaroma Risk Assessment Profile
.... 19.42 Secondary Cancer Condition Profile
.... 19.43 TNM Distant Metastases Category Profile
.... 19.44 TNM Primary Tumor Category Profile
.... 19.45 TNM Regional Nodes Category Profile
.... 19.46 TNM Stage Group Profile
.... 19.47 Tumor Marker Test Profile
.... 19.48 Tumor Morphology Report
.... 19.49 Tumor Profile
.... 19.50 Tumor Size Profile
.... 19.51 Body Structure Identifier Profile
.... 19.52 Body Location Qualifier Extension
.... 19.53 Cancer Disease Status Evidence Type Extension
.... 19.54 Histology-Morphology-Behavior Extension
.... 19.55 Laterality Qualifier Extension
.... 19.56 Normalization Basis Extension
.... 19.57 Procedure Intent Extension
.... 19.58 Radiotherapy Dose Delivered To Volume Extension
.... 19.59 Radiotherapy Modality And Technique Extension
.... 19.60 Radiotherapy Modality Extension
.... 19.61 Radiotherapy Number of Sessions Extension
.... 19.62 Radiotherapy Technique Extension
.... 19.63 Related Condition Absent Extension
.... 19.64 Related Condition Extension
.... 19.65 Treatment Termination Reason Extension (deprecated)
.... 19.66 Acute Lymphoblastic Leukemia (ALL) Risk Assessment Value Set
.... 19.67 Benign Neoplasm of Brain and CNS Disorder Value Set
.... 19.68 Binet Stage Value Set
.... 19.69 Body Location and Laterality Qualifier Value Set
.... 19.70 Body Location Qualifier Value Set
.... 19.71 Brachytherapy High Dose Rate Electronic Technique Value Set
.... 19.72 Brachytherapy High Dose Rate Technique Value Set
.... 19.73 Brachytherapy Low Dose Rate Temporary Radiation Technique Value Set
.... 19.74 Brachytherapy Modality Value Set
.... 19.75 Brachytherapy Permanent Seeds Technique Value Set
.... 19.76 Brachytherapy Pulsed Dose Rate Technique Value Set
.... 19.77 Brachytherapy Radiopharmaceutical Technique Value Set
.... 19.78 Brachytherapy Technique Value Set
.... 19.79 Breslow Depth Stage Value Set
.... 19.80 Cancer Body Location Value Set
.... 19.81 Cancer Disease Status Evidence Type Value Set
.... 19.82 Cancer Disorder Value Set
.... 19.83 Cancer Stage Type Value Set
.... 19.84 Cancer Stage Value Set
.... 19.85 Cancer Staging Method Value Set
.... 19.86 Cancer Staging Prognostic Factors Types
.... 19.87 Cancer Staging Prognostic Factors Value
.... 19.88 Cancer-Related Surgical Procedure Value Set
.... 19.89 Carbon Ion Beam Technique Value Set
.... 19.90 Carcinoma In-Situ Disorder Value Set
.... 19.91 Clark Level Value Set
.... 19.92 Clinical or Pathologic Modifier
.... 19.93 Condition Status Trend Maximum Value Set
.... 19.94 Condition Status Trend Value Set
.... 19.95 Cytologic Evidence of Malignancy Value Set
.... 19.96 Deauville Scale Value Set
.... 19.97 Electron Beam Technique Value Set
.... 19.98 FAB Classification Value
.... 19.99 FIGO Stage Value Set
.... 19.100 FIGO Staging Method Value Set
.... 19.101 Gleason Grade Value Set
.... 19.102 Histologic Behavior and Type Value Set
.... 19.103 Histologic Grade Value Set
.... 19.104 Histologic Grading System Value Set
.... 19.105 Histology Morphology Behavior Value Set
.... 19.106 History of Metastatic Malignant Neoplasm Value Set
.... 19.107 Human Specimen Type Value Set
.... 19.108 International Neuroblastoma Risk Group Staging System (INRGSS) for Neuroblastoma Risk Assessment Value Set
.... 19.109 International Neuroblastoma Staging System (INSS) for Neuroblastoma Stage Value Set
.... 19.110 International Retinoblastoma Stage Value
.... 19.111 International Staging System (ISS) for Myeloma Stage Value Set
.... 19.112 Lansky Play Performance Status VS
.... 19.113 Laterality Qualifier Value Set
.... 19.114 Lymphoma Stage Bulky Modifier Value Set
.... 19.115 Lymphoma Stage Value Modifier Value Set
.... 19.116 Lymphoma Stage Value Set
.... 19.117 Lymphoma Staging System Value Set
.... 19.118 Melanoma In-Situ Disorder Value Set
.... 19.119 Neutron Beam Technique Value Set
.... 19.120 Normalization Basis Value Set
.... 19.121 Photon Beam Technique Value Set
.... 19.122 PRETEXT Stage Value
.... 19.123 Primary Cancer Disorder Value Set
.... 19.124 Primary Malignant Neoplasm Disorder Value Set
.... 19.125 Procedure Intent Value Set
.... 19.126 Proton Beam Technique Value Set
.... 19.127 Radiotherapy Modality Value Set
.... 19.128 Radiotherapy Technique Value Set
.... 19.129 Radiotherapy Treatment Location Qualifier Value Set
.... 19.130 Radiotherapy Treatment Location Value Set
.... 19.131 Radiotherapy Volume Type Value Set
.... 19.132 Rai Stage Value Set
.... 19.133 Rai Staging System Value Set
.... 19.134 Revised International Staging System (ISS) for Multiple Myeloma Stage Value Set
.... 19.135 Rhabdomyosarcoma Assessment Value Set
.... 19.136 Rhabdomyosarcoma Clinical Group Value
.... 19.137 Risk Assessment Type Value Set
.... 19.138 Risk Assessment Value Set
.... 19.139 Secondary Cancer Disorder Value Set
.... 19.140 Specific Diagnosis of Cancer Value Set
.... 19.141 Teleradiotherapy Modality Value Set
.... 19.142 Teleradiotherapy Technique Value Set
.... 19.143 TG263 ValueSet
.... 19.144 TNM Distant Metastases Category Value Set
.... 19.145 TNM Distant Metastases Maximum Value Set
.... 19.146 TNM Distant Metastases Staging Type Maximum Value Set
.... 19.147 TNM Distant Metastases Staging Type Value Set
.... 19.148 TNM Primary Tumor Category Value Set
.... 19.149 TNM Primary Tumor Maximum Value Set
.... 19.150 TNM Primary Tumor Staging Type Maximum Value Set
.... 19.151 TNM Primary Tumor Staging Type Value Set
.... 19.152 TNM Regional Nodes Category Value Set
.... 19.153 TNM Regional Nodes Maximum Value Set
.... 19.154 TNM Regional Nodes Staging Type Maximum Value Set
.... 19.155 TNM Regional Nodes Staging Type Value Set
.... 19.156 TNM Stage Group Maximum Value Set
.... 19.157 TNM Stage Group Staging Type Maximum Value Set
.... 19.158 TNM Stage Group Staging Type Value Set
.... 19.159 TNM Stage Group Value Set
.... 19.160 TNM Staging Method Value Set
.... 19.161 Treatment Termination Reason Value Set
.... 19.162 Tumor Marker Test Value Set
.... 19.163 Tumor Morphology Code Max Value Set
.... 19.164 Tumor Morphology Code Value Set
.... 19.165 Tumor Size Method Value Set
.... 19.166 Tumor Size Units Value Set
.... 19.167 Wilms Tumor Body Site Value Set
.... 19.168 Wilms Tumor Stage Value Set
.... 19.169 TG263 CodeSystem
.... 19.170 TG263 Concept Map
.... 19.171 all-risk-assessment-high
.... 19.172 all-risk-assessment-standard-brian-l
.... 19.173 binet-stage-group-B
.... 19.174 body-surface-area-brian-l
.... 19.175 body-surface-area-example
.... 19.176 bodyheight-jenny-m-2018-03-06
.... 19.177 bodyweight-jenny-m-2018-03-16
.... 19.178 bodyweight-jenny-m-2018-04-22
.... 19.179 bone-marrow-aspirate-result-brian-l
.... 19.180 bone-marrow-biopsy-result-brian-l
.... 19.181 cancer-disease-status-improved
.... 19.182 cancer-disease-status-improved-brian-l
.... 19.183 cancer-disease-status-jenny-m
.... 19.184 cancer-patient-adam-everyman
.... 19.185 cancer-patient-brian-l
.... 19.186 cancer-patient-eve-anyperson
.... 19.187 cancer-patient-jenny-m
.... 19.188 cancer-patient-john-anyperson
.... 19.189 cancer-patient-lucy-child
.... 19.190 cancer-related-comorbidities-jenny-m
.... 19.191 cancer-related-comorbidities-john-anyperson
.... 19.192 cancer-related-medication-admin-cyclophosphamide-brian-l
.... 19.193 cancer-related-medication-admin-cyclophosphamide-jenny-m
.... 19.194 cancer-related-medication-admin-doxorubicin-jenny-m
.... 19.195 cancer-related-medication-admin-idarubicin-brian-l
.... 19.196 cancer-related-medication-admin-paclitaxel-jenny-m
.... 19.197 cancer-related-medication-admin-prednisone-brian-l
.... 19.198 cancer-related-medication-admin-vincristine-brian-l
.... 19.199 cancer-related-medication-request-anastrozole-jenny-m
.... 19.200 cancer-related-medication-request-cisplatin
.... 19.201 cancer-related-medication-request-cisplatin-stopped
.... 19.202 cancer-related-medication-request-cyclophosphamide-brian-l
.... 19.203 cancer-related-medication-request-cyclophosphamide-jenny-m
.... 19.204 cancer-related-medication-request-doxorubicin-jenny-m
.... 19.205 cancer-related-medication-request-gefitinib
.... 19.206 cancer-related-medication-request-idarubicin-brian-l
.... 19.207 cancer-related-medication-request-paclitaxel-jenny-m
.... 19.208 cancer-related-medication-request-prednisone-brian-l
.... 19.209 cancer-related-medication-request-vincristine-brian-l
.... 19.210 cancer-related-surgical-procedure-jenny-m
.... 19.211 cancer-related-surgical-procedure-lobectomy
.... 19.212 deauville-scale-five
.... 19.213 ecog-performance-status-fully-active
.... 19.214 ecog-performance-status-jenny-m
.... 19.215 family-member-history-aunt-jenny-m
.... 19.216 family-member-history-grandmother-brian-l
.... 19.217 family-member-history-sister-jenny-m
.... 19.218 family-member-history-uncle-jenny-m
.... 19.219 figo-stage-IIIA
.... 19.220 genomic-region-studied-jenny-m
.... 19.221 genomic-region-studied-stk11
.... 19.222 genomic-variant-fusion
.... 19.223 genomic-variant-germline-deletion
.... 19.224 genomic-variant-jenny-m
.... 19.225 genomic-variant-somatic-single-nucleotide
.... 19.226 genomics-report-jenny-m
.... 19.227 genomics-report-john-anyperson
.... 19.228 gleason-grade-group-4
.... 19.229 gx-cancer-patient-adam-anyperson
.... 19.230 gx-genomic-bundle-adam-anyperson
.... 19.231 gx-genomic-diagnostic-implication-bap1
.... 19.232 gx-genomic-diagnostic-implication-pof1b
.... 19.233 gx-genomic-diagnostic-implication-polrmt
.... 19.234 gx-genomic-msi
.... 19.235 gx-genomic-specimen-tumornormal-normal
.... 19.236 gx-genomic-specimen-tumornormal-tumor
.... 19.237 gx-genomic-therapeutic-implication-alectinib
.... 19.238 gx-genomic-therapeutic-implication-brigatinib
.... 19.239 gx-genomic-therapeutic-implication-ceritinib
.... 19.240 gx-genomic-therapeutic-implication-crizotinib
.... 19.241 gx-genomic-therapeutic-implication-lorlatinib
.... 19.242 gx-genomic-tmb
.... 19.243 gx-genomic-variant-fusion-ETV6-RUNX1-brian-l
.... 19.244 gx-genomic-variant-fusion-met-alk
.... 19.245 gx-genomic-variant-pertinent-negative-nras-kit-braf
.... 19.246 gx-genomic-variant-somatic-bap1-indel
.... 19.247 gx-genomic-variant-somatic-cdkn2a-cnv
.... 19.248 gx-genomic-variant-somatic-cdkn2b-cnv
.... 19.249 gx-genomic-variant-somatic-kdm5d
.... 19.250 gx-genomic-variant-somatic-mtap
.... 19.251 gx-genomic-variant-somatic-mycn
.... 19.252 gx-genomic-variant-somatic-pof1b
.... 19.253 gx-genomic-variant-somatic-polrmt
.... 19.254 gx-genomics-report-adam-anyperson
.... 19.255 gx-order-tumornormal-gensop-inc
.... 19.256 gx-practitioner-test-pathologist
.... 19.257 gx-us-core-organization-gensop-inc
.... 19.258 hematocrit-brian-l
.... 19.259 hemoglobin-brian-l
.... 19.260 histologic-behavior-and-type-non-small-cell
.... 19.261 histologic-grade-intermediate
.... 19.262 history-of-cancer-metastatic-to-liver
.... 19.263 hodgkins-lymphoma-stage-IIIe
.... 19.264 human-specimen-left-breast-jenny-m
.... 19.265 human-specimen-lung
.... 19.266 immunophenotype-brian-l
.... 19.267 jenny-m-chest-wall-lymph-nodes-treatment-volume
.... 19.268 jenny-m-chest-wall-treatment-volume
.... 19.269 john-anyperson-chf
.... 19.270 john-anyperson-hd
.... 19.271 john-anyperson-treatment-volume
.... 19.272 karnofsky-performance-status-normal-activity
.... 19.273 lab-result-observation-hemoglobin
.... 19.274 lansky-performance-status-brian-l
.... 19.275 lansky-play-performance-status-twenty
.... 19.276 mCODE Patient Group Example
.... 19.277 mcode-patient-bundle-jenny-m
.... 19.278 melanoma-breslow-depth-stage
.... 19.279 melanoma-clark-level-4
.... 19.280 multiple-myeloma-iss-stage-II
.... 19.281 multiple-myeloma-riss-stage-II
.... 19.282 neuroblastoma-inrgss-stage-MS
.... 19.283 neuroblastoma-inss-stage-III
.... 19.284 no-history-of-metastatic-cancer
.... 19.285 observation-smoking-pack-years-jenny-m
.... 19.286 primary-cancer-condition-breast
.... 19.287 primary-cancer-condition-brian-l
.... 19.288 primary-cancer-condition-cll
.... 19.289 primary-cancer-condition-jenny-m
.... 19.290 primary-cancer-condition-nonspecific
.... 19.291 primary-cancer-condition-nsclc
.... 19.292 radiotherapy-treatment-summary-chest-wall-jenny-m
.... 19.293 radiotherapy-treatment-summary-other-with-text
.... 19.294 rai-stage-II
.... 19.295 rhabdomyosarcoma-clinical-group-stage-IA
.... 19.296 rhabdomyosarcoma-risk-assessment-low
.... 19.297 secondary-cancer-condition-brain-mets
.... 19.298 tnm-clinical-distant-metastases-category-cM0
.... 19.299 tnm-clinical-distant-metastases-category-jenny-m
.... 19.300 tnm-clinical-primary-tumor-category-cT3
.... 19.301 tnm-clinical-primary-tumor-category-jenny-m
.... 19.302 tnm-clinical-regional-nodes-category-cN3
.... 19.303 tnm-clinical-regional-nodes-category-jenny-m
.... 19.304 tnm-clinical-stage-group-3c
.... 19.305 tnm-clinical-stage-group-jenny-m
.... 19.306 tnm-pathologic-distant-metastases-category-jenny-m
.... 19.307 tnm-pathologic-primary-tumor-category-jenny-m
.... 19.308 tnm-pathologic-regional-nodes-category-jenny-m
.... 19.309 tnm-pathologic-stage-group-jenny-m
.... 19.310 tumor-lobular-carcinoma-left-breast
.... 19.311 tumor-marker-test-egf
.... 19.312 tumor-marker-test-er-jenny-m
.... 19.313 tumor-marker-test-her2-jenny-m
.... 19.314 tumor-marker-test-oncotype-dx-jenny-m
.... 19.315 tumor-marker-test-pr-jenny-m
.... 19.316 tumor-morphology-report-non-small-cell-intermediate-grade
.... 19.317 tumor-size-jenny-m
.... 19.318 tumor-size-pathology
.... 19.319 tumor-specimen-left-breast-jenny-m
.... 19.320 tumor-specimen-lobular-carcinoma-left-breast
.... 19.321 us-core-condition-anxiety-jenny-m
.... 19.322 us-core-condition-atrial-septal-defect-brian-l
.... 19.323 us-core-condition-depression-jenny-m
.... 19.324 us-core-condition-hypertension-jenny-m
.... 19.325 us-core-diagnosticreport-cbc-brian-l
.... 19.326 us-core-diagnosticreport-lab-jenny-m
.... 19.327 us-core-lumbar-puncture-result-brian-l
.... 19.328 us-core-observation-lab-neutrophils-jenny-m
.... 19.329 us-core-observation-lab-sentinel-nodes-jenny-m
.... 19.330 us-core-observation-lab-tumor-dcis-jenny-m
.... 19.331 us-core-observation-lab-tumor-grade-jenny-m
.... 19.332 us-core-observation-lab-tumor-invasion-jenny-m
.... 19.333 us-core-observation-lab-tumor-margins-jenny-m
.... 19.334 us-core-organization-bedrock-medicine
.... 19.335 us-core-organization-physician-services-inc
.... 19.336 us-core-practitioner-jane-radiotech
.... 19.337 us-core-practitioner-kyle-anydoc
.... 19.338 us-core-practitioner-mary-obgyn
.... 19.339 us-core-practitioner-nancy-oncology-nurse
.... 19.340 us-core-practitioner-owen-oncologist
.... 19.341 us-core-practitioner-peter-pathologist
.... 19.342 us-core-procedure-biopsy-jenny-m
.... 19.343 us-core-procedure-bone-marrow-aspiration-brian-l
.... 19.344 us-core-procedure-bone-marrow-biopsy-brian-l
.... 19.345 us-core-procedure-lumbar-puncture-brian-l
.... 19.346 us-core-procedure-mammogram-jenny-m
.... 19.347 us-core-smokingstatus-jenny-m
.... 19.348 white-blood-cell-brian-l
.... 19.349 wilms-tumor-stage-III
... 20 Basic Examples
... 21 Genomics Examples
... 22 Extended Example
... 23 Extended Pediatric Example
... 24 Release Notes
... 25 Glossary
... 26 Download Specification
... 27 mCODE Implementation Guide Resource